Artificial intelligence-focused biotech Isomorphic Labs is getting another big infusion of funding to further develop its drug-design system and also to advance some of its programs into the clinic, on top of partnerships with two major drug makers that it announced at the beginning of 2024. It also adds to a slew of financings, acquisitions and partnerships involving AI-based biotech companies throughout 2024.
London-based Isomorphic said 31 March that it raised $600m in its first external funding round, which Thrive Capital led, while Google Ventures and Alphabet – whose DeepMind subsidiary Isomorphic spun...
Key Takeaways
- Spun out from Google DeepMind, Isomorphic Labs said it raised $600m in its first external funding round, which Thrive Capital led.
- The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?